Among the most widely used are IL-6 inhibitors, such as tocilizumab and sarilumab, which have demonstrated clinical efficacy in rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis, and giant cell arteritis (87). This evidence concerns the gene IL6 and rheumatoid arthritis.